Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells metformin active pharmaceutical ingredients and direct compressible granulates for the pharmaceutical industry worldwide.
The last earnings update was 115 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Vistin Pharma. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Vistin Pharma's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vistin Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Vistin Pharma's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Vistin Pharma's earnings growth to the Norway market average as no estimate data is available.
Unable to compare Vistin Pharma's revenue growth to the Norway market average as no estimate data is available.
Unable to determine if Vistin Pharma is high growth as no earnings estimate data is available.
Unable to determine if Vistin Pharma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Vistin Pharma's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Kjell-Erik Nordby, M.Sc., M.B.A., has been the Chief Executive Officer of Vistin Pharma ASA since June 1, 2015. Mr. Nordby served as the Chief Executive Officer of Weifa ASA from February 2009 to June 1, 2015. He served as Chief Executive Officer of Weifa AS since February 2009. He served as Vice President and Director of Business Development of PCI Biotech Holding ASA (formerly known as Photocure ASA) since April 2007. Mr. Nordby has an extensive experience in business development, marketing and sales. He served at Alpharma (API Business Development) as the Vice President of Sales & Marketing of North Europe and served as its Senior Director for Business Development and Project Portfolio Management. He served as a Director of Navamedic ASA since May 2012. He holds an MBA of Honor from the Norwegian School of Management, a degree in International Marketing from the Norwegian School of Management and a Master of Science in Pharmacy from the University of Oslo.
Kjell-Erik's compensation has been consistent with company performance over the past year, both up more than 20%.
Kjell-Erik's remuneration is about average for companies of similar size in Norway.
Chief Executive Officer
Interim Chief Financial Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Vistin Pharma board of directors is less than 3 years, this suggests a new board.
Board of Directors
Employee Representative Director
Employee Representative Director
Who owns this company?
Recent Insider Trading
More shares have been bought than sold by Vistin Pharma individual insiders in the past 3 months.
Does Vistin Pharma ASA's (OB:VISTIN) CEO Salary Reflect Performance?
See our latest analysis for Vistin Pharma How Does Kjell-Erik Nordby's Compensation Compare With Similar Sized Companies? … It would therefore appear that Vistin Pharma ASA pays Kjell-Erik Nordby more than the median CEO remuneration at companies of a similar size, in the same market. … We compared total CEO remuneration at Vistin Pharma ASA with the amount paid at companies with a similar market capitalization.
Have Insiders Been Selling Vistin Pharma ASA (OB:VISTIN) Shares This Year?
So before you buy or sell Vistin Pharma ASA (OB:VISTIN), you may well want to know whether insiders have been buying or selling. … Check out our latest analysis for Vistin Pharma The Last 12 Months Of Insider Transactions At Vistin Pharma The Chief Operating Officer, Valborg Vold, made the biggest insider sale in the last 12 months. … OB:VISTIN Recent Insider Trading, July 19th 2019 Insider Ownership of Vistin Pharma For a common shareholder, it is worth checking how many shares are held by company insiders.
What Kind Of Shareholders Own Vistin Pharma ASA (OB:VISTIN)?
Every investor in Vistin Pharma ASA (OB:VISTIN) should be aware of the most powerful shareholder groups. … Check out our latest analysis for Vistin Pharma OB:VISTIN Ownership Summary, May 30th 2019 What Does The Institutional Ownership Tell Us About Vistin Pharma? … Insider Ownership Of Vistin Pharma The definition of an insider can differ slightly between different countries, but members of the board of directors always count.
Is Vistin Pharma ASA's (OB:VISTIN) CEO Salary Justified?
Kjell-Erik Nordby has been the CEO of Vistin Pharma ASA (OB:VISTIN) since 2015. … This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Kjell-Erik Nordby's Compensation Compare With Similar Sized Companies?
How Much Are Vistin Pharma ASA (OB:VISTIN) Insiders Taking Off The Table?
So shareholders might well want to know whether insiders have been buying or selling shares in Vistin Pharma ASA (OB:VISTIN). … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … Vistin Pharma Insider Transactions Over The Last Year.
What Kind Of Investor Owns Most Of Vistin Pharma ASA (OB:VISTIN)?
If you want to know who really controls Vistin Pharma ASA (OB:VISTIN), then you'll have to look at the makeup of its share registry. … With a market capitalization of øre341m, Vistin Pharma is a small cap stock, so it might not be well known by many institutional investors. … See our latest analysis for Vistin Pharma
Is Vistin Pharma ASA (OB:VISTIN) A Financially Sound Company?
The direct benefit for Vistin Pharma ASA (OB:VISTIN), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Does VISTIN's growth rate justify its decision for financial flexibility over lower cost of capital … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital.
Our Take On Vistin Pharma ASA's (OB:VISTIN) CEO Salary
This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Kjell-Erik Nordby's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that Vistin Pharma ASA has a market cap of øre324m, and is paying total annual CEO compensation of øre5.3m.
What Kind Of Investor Owns Most Of Vistin Pharma ASA (OB:VISTIN)?
A look at the shareholders of Vistin Pharma ASA (OB:VISTIN) can tell us which group is most powerful. … Taking a look at the our data on the ownership groups (below), it's seems that. … See our latest analysis for Vistin Pharma
What Investors Should Know About Vistin Pharma ASA's (OB:VISTIN) Financial Strength
However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is VISTIN right in choosing financial flexibility over lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells metformin active pharmaceutical ingredients and direct compressible granulates for the pharmaceutical industry worldwide. Vistin Pharma ASA was founded in 2015 and is headquartered in Oslo, Norway.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.